PMID- 30686534
OWN - NLM
STAT- MEDLINE
DCOM- 20191112
LR  - 20191112
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 510
IP  - 2
DP  - 2019 Mar 5
TI  - The release and activity of HMGB1 in ferroptosis.
PG  - 278-283
LID - S0006-291X(19)30103-2 [pii]
LID - 10.1016/j.bbrc.2019.01.090 [doi]
AB  - Damage-associated molecular pattern molecules (DAMPs) are endogenous danger 
      signals that alert the innate immune system and shape the inflammation response 
      to cell death. However, the release and activity of DAMPs in ferroptosis, a 
      recently identified form of regulated necrosis characterized by iron overload and 
      lipid peroxidation, still remain poorly understood. Here, we demonstrate that 
      HMGB1 is a DAMP released by ferroptotic cells in an autophagy-dependent manner. 
      Both type I and II ferroptosis activators, including erastin, sorafenib, RSL3, 
      and FIN56, induce HMGB1 release in cancer and noncancer cells. In contrast, 
      genetic ablation (using ATG5(-/-) or ATG7(-/-) cells) or pharmacologic inhibition 
      (the administration of bafilomycin A1 or chloroquine) of autophagy was found to 
      block ferroptosis activator-induced HMGB1 release. Mechanically, 
      autophagy-mediated HDAC inhibition promotes HMGB1 acetylation, resulting in HMGB1 
      release in ferroptosis. Moreover, AGER, but not TLR4, is required for 
      HMGB1-mediated inflammation in macrophages in response to ferroptotic cells. 
      These studies suggest that HMGB1 inhibition might have some potential therapeutic 
      effects in ferroptosis-associated human disease.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Wen, Qirong
AU  - Wen Q
AD  - The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 
      Guangdong, 510510, China.
FAU - Liu, Jiao
AU  - Liu J
AD  - The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 
      Guangdong, 510510, China.
FAU - Kang, Rui
AU  - Kang R
AD  - Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Zhou, Borong
AU  - Zhou B
AD  - The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 
      Guangdong, 510510, China. Electronic address: zhoubr8@aliyun.com.
FAU - Tang, Daolin
AU  - Tang D
AD  - Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA. 
      Electronic address: daolin.tang@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190125
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Carbolines)
RN  - 0 (FIN56 compound)
RN  - 0 (HMGB1 Protein)
RN  - 0 (HMGB1 protein, human)
RN  - 0 (HMGB1 protein, mouse)
RN  - 0 (Macrolides)
RN  - 0 (Oximes)
RN  - 0 (Piperazines)
RN  - 0 (RSL3 compound)
RN  - 0 (Sulfonamides)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (erastin)
RN  - 886U3H6UFF (Chloroquine)
RN  - 88899-55-2 (bafilomycin A1)
RN  - 9007-73-2 (Ferritins)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Animals
MH  - *Autophagy
MH  - Carbolines/pharmacology
MH  - *Cell Death
MH  - Cell Line, Tumor
MH  - Chloroquine/pharmacology
MH  - Ferritins/metabolism
MH  - Fibroblasts/metabolism
MH  - HMGB1 Protein/*metabolism
MH  - Humans
MH  - Immunity, Innate
MH  - Inflammation
MH  - Iron Overload
MH  - Lipid Peroxidation
MH  - Macrolides/pharmacology
MH  - Mice
MH  - Neoplasms
MH  - Oximes/pharmacology
MH  - Piperazines/pharmacology
MH  - Sorafenib/pharmacology
MH  - Sulfonamides/pharmacology
MH  - Toll-Like Receptor 4/metabolism
OTO - NOTNLM
OT  - AGER
OT  - Autophagy
OT  - DAMP
OT  - Ferroptosis
OT  - HMGB1
OT  - Inflammation
EDAT- 2019/01/29 06:00
MHDA- 2019/11/13 06:00
CRDT- 2019/01/29 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/01/18 00:00 [accepted]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2019/11/13 06:00 [medline]
PHST- 2019/01/29 06:00 [entrez]
AID - S0006-291X(19)30103-2 [pii]
AID - 10.1016/j.bbrc.2019.01.090 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2019 Mar 5;510(2):278-283. doi: 
      10.1016/j.bbrc.2019.01.090. Epub 2019 Jan 25.